论文部分内容阅读
目的分析聚乙二醇干扰素α-2a联合利巴韦林治疗慢性丙型肝炎(CHC)的疗效及疗效影响因素。方法选取确诊CHC患者96例。给予PEG-IFNα-2a(派罗欣,180μg/周)联合利巴韦林(600~1200mg/d)治疗。分别于治疗前后检测肝功能、HCV-RNA量和HCV基因型。分析其疗效,以及多种因素与疗效的相关性。结果治疗中ER率为60.4%,疗程结束时TR、PR、NR率为68.8%、22.9%、8.3%,随访24周SR率为57.3%,复发率为10.4%。TR患者基因非Ⅰ型比例、低HCV-RNA水平比例和ER率显著高于非TR患者,而年龄和肝硬化比例显著低于非TR患者,差异有统计学意义(P<0.05)。结论 PEG-IFNα-2a联合利巴韦林治疗CHC疗效显著;年龄、肝硬化、早期应答率、基因型、HCV-RNA水平可能与其疗效影响因素。
Objective To analyze the curative effect and efficacy of pegylated interferon α-2a combined with ribavirin in the treatment of chronic hepatitis C (CHC). Methods 96 cases diagnosed CHC patients. Administration of PEG-IFNα-2a (PEGASYS, 180 μg / week) in combination with ribavirin (600-1200 mg / d). Liver function, HCV-RNA content and HCV genotype were detected before and after treatment. Analysis of its efficacy, as well as a variety of factors and the efficacy of the correlation. Results The ER rate was 60.4%. The TR, PR and NR rates at the end of treatment were 68.8%, 22.9% and 8.3% respectively. The SR rate was 57.3% and the recurrence rate was 10.4% at 24 weeks follow-up. The proportion of non-type I, low HCV-RNA and ER in TR patients were significantly higher than those in non-TR patients, while the proportion of age and cirrhosis was significantly lower than that in non-TR patients (P <0.05). Conclusions PEG-IFNα-2a combined with ribavirin has significant curative effect on CHC. Age, cirrhosis, early response rate, genotype and HCV-RNA level may be related to its therapeutic effect.